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TAVI programmes are generally delivered by a multi-disciplinary 
team (MDT) consisting of interventional cardiologists, cardiac sur-
geons, cardiac anaesthetists and imaging specialists. Increasingly it 
is also recommended that a physician with an expertise in the care 
of the elderly should be included in the team. The selection of 
optimal patients is one of the most critical factors contributing to 
the success of a TAVI programme, requiring the expert assessment 
of each member of the MDT.
CLINICAL ASSESSMENT
Aortic valve replacement is generally recommended for patients 
who are symptomatic. Careful clinical assessment is mandatory to 
ensure that the signs and symptoms are indeed due to severe aortic 
stenosis and that replacing the valve is expected to improve the 
patient’s condition.
The risk of sAVR must then be assessed. As this is an operative risk 
assessment, it is essential to include the opinion of a cardiac surgeon 
in the process.
 
SURGICAL RISK ASSESSMENT
Thus far, no risk score has been designed specifically for TAVI. 
Traditionally the logistic EuroSCORE(6) and Society of Thoracic 
INTRODUCTION
Severe symptomatic aortic stenosis carries a very poor prognosis 
with 1 year survival in the region of only 75%.(1) Surgical aortic valve 
replacement (sAVR) improves survival.(2) However, as the co-
morbidities and age of patients with aortic stenosis increase so does 
the operative mortality while one-year survival decreases  such that 
octogenarians with a logistic EuroSCORE of >20% have a 1 year 
survival of only around 70% after sAVR.(3,4)
Transcatheter aortic valve implantation (TAVI) is a catheter based 
technique which allows replacement of the aortic valve without 
requiring sternotomy or cardiopulmonary bypass. It has been 
designed to treat patients who are high risk for conventional 
surgery. The first TAVI procedure was performed by Alain Cribier 
in 2002.(5)
Currently 2 TAVI devices are available. The MedtronicTM Core-
ValveTM is a self-expanding device which delivers a porcine peri-
cardial valve. The Edwards SAPIENTM device is balloon expandable 
and delivers a bovine pericardial valve. Details of these technologies 
are dealt with in accompanying articles in an earlier edition of this 
journal [SA Heart 2012; 9 (1)]. 
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COMMENTARY
Patient selection is likely to be the most important deter-
minant of a successful long term outcome of the TAVI pro-
cedure. It requires careful assessment of the indications for 
aortic valve replacement, clinical status of the patient, 
associated co-morbidities and, importantly, the cognitive 
function and motivation of the patient. This assessment 
must be made by a multi-disciplinary team consisting of 
at least a cardiologist, cardiac surgeon, anaesthetist and 
general physician. Careful imaging of the relevant anatomy 
with ultrasound and CT scanning is critical. Experience 
improves patient selection and ultimate outcome. Funding 
remains a challenge and many patients worthy of the pro-
cedure are denied because of costs.  SAHeart 2012; 9:90-95
91
A
ut
um
n 
20
12
Vo
lu
m
e 
9 
• 
N
um
be
r 2
Surgeons (STS)(7) scores have been used to assess suitability for 
TAVI and as guidelines for registries and trials (with a logistic 
EuroSCORE of >20% and an STS score of >10 being considered 
indications for TAVI), but both are far from ideal with especially 
the EuroSCORE overestimating risk. There are a number of fact-
ors which increase the risk of surgery that are not adequately 
reflected in the traditional risk scores e.g. mobility, frailty and a 
porcelain aorta. For this reason using a logistic EuroSCORE of 
>20% as the indication for TAVI will result in some “appropriate” 
patients being excluded and vice versa. A specific risk score for 
TAVI needs to be developed.
Once the patient has been considered a high risk for surgery he/she 
must then undergo a number of screening investigations which will 
allow the MDT to decide whether sAVR, TAVI or medical therapy 
is the most appropriate route to follow.
SCREENING INVESTIGATIONS
Screening investigations should include echocardiography, angio-
graphy, CT scanning, lung function tests, carotid Doppler, blood 
tests that include an assessment of renal function and an assessment 
of frailty.
Echocardiography gives useful information about aortic valve 
function and morphology, left ventricular function and size, mitral 
valve function and the presence or absence of a septal bulge. 
Measurement of the aortic annulus diameter is critical. There is no 
real consensus on how best to measure the aortic annulus but 
many favour transoesophageal echocardiography. It is widely 
accepted that the annulus is elliptical rather than circular, which 
may contribute to the frequent paravalvar leaks seen after TAVI 
implants, hence increasing the need for more accurate assessment 
by 3D echocardiography and/or CT scanning. The final decision 
on prosthetic valve size to be implanted should not be based on 
a single measurement of annular size, but rather on assessment of 
the whole of the aortic root including annulus size, morphology and 
degree of calcification of the native leaflets, size of the sinuses of 
Valsalva and the degree of aortic calcification. The placement of a 
large valve in women with a porcelain aorta runs a risk of annular 
rupture, a disastrous and usually fatal complication.
The coronary anatomy and also (potentially) the peripheral vascu-
lature may be assessed by angiography. Not only is the size of the 
femoral and iliac vessels important, but also the extent of tortuosity 
and the degree of calcification. CT scanning of the whole of the 
aorta with or without contrast should be used in addition to 
peripheral angiography. In the presence of renal dysfunction, due 
caution must be taken to avoid contrast-induced nephropathy. 
Even contrast free CT scanning yields important information about 
the degree of calcification of the thoracic aorta (to diagnose 
porcelain aorta) and also the femoral and iliac circulation. Accurate 
interpretation of the CT images requires an experienced radiologist 
whose input to the MDT can be most useful.
Elderly patients with aortic stenosis and poor lung function 
represent a particularly challenging group. It is not only important 
to assess the relative contribution of respiratory and aortic 
pathology to breathlessness but also whether the degree of respi-
ratory problems might lead to major post-procedural pulmonary 
problems and ultimately respiratory death. Detailed pulmonary 
function tests should be performed. A number of factors assist in 
judging the cause of a patient’s dyspnoea. A short history and an 
elevated proBNP suggest cardiac rather than respiratory pathology. 
Also, initially assessing the response to balloon aortic valvuloplasty 
(BAV) can be useful. An important symptomatic improvement after 
BAV suggests that a subsequent TAVI will benefit the patient. 
However, despite these measures, patients with poor lung function 
remain a considerable problem. After TAVI, 10-15% of patients 
who die between 30 days and one year suffer a non-cardiac 
respiratory death.(8) It is clear that more sensitive measures of lung 
function are required in order to identify these at-risk patients 
before the procedure. 
Patient frailty is difficult to estimate but may have an important 
bearing on the immediate and longer term success of a TAVI 
procedure. There is no standardized risk score model for frailty as 
an index of risk for general surgery or TAVI. Various models have 
been proposed incorporating a number of factors such as walking 
distance/speed, weight loss, strength and balance, nutritional status 
and independent daily living activities (washing, dressing driving 
etc.). With better equipment, percutaneous closure of groin sites 
and anticipated greater use of the transaortic approach, the actual 
trauma to the patient is becoming less and physical frailty less of 
an obstacle. 
As teams become more experienced the “eyeball” test becomes 
quite accurate and we consider factors such as mental and emo-
tional status, particularly as to whether the patient understands the 
implications of the procedure and is enthusiastic towards going 
through with it, as important factors towards yielding a successful 
outcome. The MDT member with expertise in care of the elderly 
is most suited to carry out this assessment. However thus far no 
consensus has been reached on which of the variety of the 
measures used previously or presently under development should 
be employed for TAVI.(9)
MEETING OF THE MULTI-DISCIPLINARY 
TAVI TEAM (MDT)
The patient data should be presented to a joint meeting of the 
MDT once the screening tests have been completed, from which 
1 of 3 possible recommendations could be made:
 ■ The patient may be considered inappropriate for either sAVR 
or TAVI. The team may feel that the benefits to the patient 
would be small and the risks exceedingly high due to co-
morbidities or frailty. For example, patients with cancer who 
have a prognosis of less than one year should not be offered 
TAVI. In the South African experience, 20% of patients who 
are discussed are found not to be appropriate for surgery or 
TAVI (Figure 1). These tend to be the highest risk patients 
with the poorest outcome. A palliative BAV might be con-
sidered in this group in an attempt to alleviate symptoms in 
the short term.
PATIENT SELECTION FOR TAVI
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FIGURE 1: Outcome of 400 patients referred into the TAVI programme at St Thomas’ Hospital, London for assessment by the 
multi-disciplinary team (MDT).
400 patients
13 (3.3%) 
declined screening
9 (2.3%) 
declined TAVI
29 (7.25%) 
moderate AS
97 (24%) 
medical therapy
41 (10%) BAV
followed by medical therapy
56 (14%) 
medical therapy alone
52 (13%) 
conventional surgery
158 (39.5%) 
TAVI
11 (2.75%) 
died pre screening
19 (4.75%) 
died on TAVI waiting list
12 (3%) 
annulus wrong size
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 ■ The patient may be assessed as suitable and appropriate for 
TAVI. About 60% of patients referred to the TAVI programme 
are considered to be appropriate candidates for TAVI. How-
ever, only 40% of these eventually undergo the procedure 
because of funding difficulties or patients declining. The MDT 
must also decide on the access route for the TAVI; trans-
femoral, transapical, subclavian or transaortic. Most units adopt 
the default position of transfemoral first, and there is some 
evidence that the outcomes of transfemoral access are better 
than transapical which is not entirely due to the increased co-
morbidities of patients treated via the transapical route. Patients 
requiring a preparatory procedure such as coronary angioplasty 
or BAV should have this performed in staged fashion prior 
to TAVI.
 ■ About 20% of patients may be appropriate for open surgical 
AVR. 
CORONARY ANGIOPLASTY PRIOR TO TAVI
The majority of TAVI patients present with breathlessness or 
syncope rather than chest pain. During sAVR it is traditional to 
bypass any major epicardial stenosis. Despite this the need for 
revascularisation prior to TAVI in the absence of chest pain is 
unclear. Theoretically revascularisation of important proximal major 
coronary artery lesions could improve the safety of the procedure 
or the longer term outcome but as yet there is no objective data to 
support this. 
FIGURE 2:  How to measure cost effectiveness.
Medical therapy alone
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After the implant
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Defi nition
The incremental cost effectiveness ratio (ICER) defines what additional cost is to be invested to gain one additional unit of effective-
ness (e.g. quality-adjusted life year, QALY) with a new therapy as compared to an alternative therapy.
Quality Adjusted Life Years (QALYs)
 ■ Is a common measure of benefit that combines quantity and quality of life.
 ■ Is calculated by weighing each year of life with a quality of life score (called “utility”). A utility of 1 means perfect health while a 
utility of 0 means death.
Systematic angioplasty of coronary lesions in this circumstance is 
probably not justified. Because of the danger of resistant ischaemia 
during rapid pacing and TAVI deployment, a pragmatic approach 
may be to consider PCI to left main or proximal LAD lesions. In 
order to improve LV function prior to TAVI, an even more 
extensive PCI strategy may be considered if the left ventricular 
function is poor. Both strategies are intended to improve the safety 
of TAVI. However, the effect of revascularisation on longer term 
outcomes requires further investigation.
BAV PRIOR TO TAVI
The benefits of standalone BAV are short-lived and the risk is not 
insignificant. Thus BAV became a forgotten technique at a time 
when there was no definitive follow-on procedure. There has been 
an important resurgence of BAV in the TAVI era. BAV can now be 
considered as a staging procedure prior to TAVI in patients who 
present with syncope, poor LV function, or those in whom the 
relative significance of cardiac and pulmonary dysfunction is unclear.
COST-EFFECTIVENESS
Patient selection and pre-procedural risk have major effects on 
the cost-effectiveness of TAVI. Cost-effectiveness is generally 
measured as cost per quality adjusted life year gained (cost/
QUALY). A QUALY is measured as a product of survival and 
quality of life. 
Figure 2 shows a theoretic situation comparing medical therapy 
with a TAVI in patients with severe symptomatic aortic stenosis. 
A medically treated patient lives for 1 year with a notional quality 
of life of 0.4 (with 1 being normal). This patient therefore has a 
QUALY of 1 x 0.4 = 0.4. If TAVI is performed the patient may live 
for two years with a quality of life improved at 0.7. This patient’s 
QUALY is 2 x 0.7 = 1.4. The patient therefore gained 1 QUALY. 
From the healthcare perspective, the question is at what the cost 
of this benefit is achieved. The acceptable price of this benefit will 
vary between different health economies. In the United Kingdom 
the National Institute of Clinical Excellence has decreed that 
£20 000 - £30 000 is acceptable for this level of benefit. A cost-
effectiveness analysis of the PARTNER Cohort B trial comparing 
TAVI with medical therapy in high risk symptomatic patients with 
aortic stenosis showed that in the TAVI group total costs were 
significantly lower at 12-month follow up ($29 352 vs. $52 724 
p<.001) with a cost-effectiveness ratio of $50 212 per life-
year gained(10) close to the $50 000 regarded as acceptable for 
new technologies in USA.(10) Cost effectiveness data from the 
PARTNER Cohort A patients comparing TAVI with surgical AVR 
is keenly awaited.
TAVI is not available yet to any State funded patients. In the pri-
vate sector, the financial situation of each patient has a major 
bearing on patient “selection”. South Africa, with its fragmented 
private health funding system, has no guidelines as to what an 
economically acceptable cost threshold may be. To date, the 
financial arrangements for each patient considered for TAVI have 
been negotiated between the patient and the particular funder. 
Different funders have different regulations. In most cases the 
patients have had to agree to some form of co-payment. Some 
have been declined outright and a few have been accepted at 
PATIENT SELECTION FOR TAVI
94
FIGURE 3: Identifying the “sweet spot” of risk may aid 
cost effectiveness.
(Adapted from a graph presented at Transcatheter Cardiovascular 
Therapeutics 21st Annual Scientifi c Symposium [TCT 2009]  
September 21 - 26, 2009; San Francisco, California.)
Cost effectiveness of TAVI
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“fee-for-service” rates despite the lack of specific codes for the 
procedure.
In the case of TAVI the aim of patient selection is to identify the 
“sweet spot” of risk where TAVI may have a mortality benefit and 
quality of life benefits equal to surgery (Figure 3). It is likely that 
very high risk patients will derive little benefit from either TAVI or 
sAVR. In very low risk patients (for whom sAVR is relatively 
inexpensive with excellent outcomes) it will be very difficult for 
TAVI to become a more cost-effective option given the current 
cost of the devices. The equation is expected to change as 
competitors enter the market and drive device costs down.
CONCLUSIONS
Optimal patient selection for the TAVI procedure is central to 
obtaining success with the procedure. Declining a very high risk 
case is preferable to a procedure which ends in failure. Patient 
selection must be made by a MDT. Optimising risk selection 
ensures that maximal cost-effectiveness will be obtained from 
the procedure.
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